Genprex Inc
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
GNPX$2.06-0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
| Year Ended | ||
|---|---|---|
| December 31, | ||
| 2023 | 2022 | |
| Revenues | $— | $— |
| Cost and expenses: | ||
| Depreciation | 15,004 | 25,575 |
| Research and development | 17,616,605 | 11,510,074 |
| General and administrative | 13,443,961 | 12,295,070 |
| Total costs and expenses | 31,075,570 | 23,830,719 |
| Operating loss | (31,075,570) | (23,830,719) |
| Interest income | 215,109 | 90,098 |
| Net loss | $(30,860,461) | $(23,740,621) |
| Net loss per share — basic and diluted | $(22.56) | $(19.80) |
| Weighted average number of common shares — basic and diluted | 1,367,747 | 1,198,837 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.